PROGRAM CHAIR
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, MA
FACULTY PRESENTERS
Tiffany Tanaka, MD
Associate Professor
Division of Blood & Marrow Transplantation
UC San Diego Moores Cancer Center
San Diego, CA
PROGRAM OVERVIEW
This enduring activity has been designed for healthcare professionals to address the needs of patients with lower-risk myelodysplastic syndrome. In particular, the education will help learners diagnose myelodysplastic syndrome earlier and accurately stratify risk; recognize potential resistant to initial therapy in patients with lower-risk myelodysplastic syndrome; and apply best evidence-based practices and clinical data for initial and second-line therapeutic decisions for lower-risk myelodysplastic syndrome.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary health care professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Interpret diagnostic criteria to enable early diagnosis of myelodysplastic syndrome with accurate risk stratification
- Evaluate the potential for resistance to initial therapy in patients with lower-risk myelodysplastic syndrome
- Use current evidence-based best practices and clinical data to inform choice of first- and second-line therapeutic options for patients with lower-risk myelodysplastic syndrome
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Faculty Member | Disclosures |
Daniel J. DeAngelo, MD | Discloses that he has received consulting fees from Amgen, Autolus Therapeutics, Blueprint, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Servier and Takeda. He has also received grant/research funding from AbbVie, Novartis, Blueprint, and Glycomimetic. |
Tiffany Tanaka, MD | Discloses that she has received consulting fees from Gilead Sciences, Inc., CTI BioPharma, and SurvivorNet. She has also had contracted research with Function Oncology. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg. physical, dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, MA
PROGRAM OVERVIEW
This enduring activity has been designed for healthcare professionals to address the needs of patients with lower-risk myelodysplastic syndrome. In particular, the education will help learners diagnose myelodysplastic syndrome earlier and accurately stratify risk; recognize potential resistant to initial therapy in patients with lower-risk myelodysplastic syndrome; and apply best evidence-based practices and clinical data for initial and second-line therapeutic decisions for lower-risk myelodysplastic syndrome.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary health care professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Interpret diagnostic criteria to enable early diagnosis of myelodysplastic syndrome with accurate risk stratification
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activityfor a maximum of .33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Faculty Member | Disclosures |
Daniel J. DeAngelo, MD | Discloses that he has received consulting fees from Amgen, Autolus Therapeutics, Blueprint, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Servier and Takeda. He has also received grant/research funding from AbbVie, Novartis, Blueprint, and Glycomimetic. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg. physical, dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
PROGRAM CHAIR
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, MA
PROGRAM OVERVIEW
This enduring activity has been designed for healthcare professionals to address the needs of patients with lower-risk myelodysplastic syndrome. In particular, the education will help learners diagnose myelodysplastic syndrome earlier and accurately stratify risk; recognize potential resistant to initial therapy in patients with lower-risk myelodysplastic syndrome; and apply best evidence-based practices and clinical data for initial and second-line therapeutic decisions for lower-risk myelodysplastic syndrome.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary health care professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Evaluate the potential for resistance to initial therapy in patients with lower-risk myelodysplastic syndrome
- Use current evidence-based best practices and clinical data to inform choice of first- and second-line therapeutic options for patients with lower-risk myelodysplastic syndrome
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of .33 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Faculty Member | Disclosures |
Daniel J. DeAngelo, MD | Discloses that he has received consulting fees from Amgen, Autolus Therapeutics, Blueprint, Gilead, Incyte, Jazz Pharmaceuticals, Novartis, Pfizer, Servier and Takeda. He has also received grant/research funding from AbbVie, Novartis, Blueprint, and Glycomimetic. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Program Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg. physical, dietary, etc.). Please contact Med Learning Group prior to participating at [email protected]
Please listen to the podcast below:
RELEASED DATE: September 29, 2023
EXPIRATION DATE: September 29, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Maya Bloomberg, MSN, APRN
Hematology Nurse Practitioner
Sylvester Comprehensive Cancer Center
Jackson Memorial Hospital
Miami, FL
PROGRAM OVERVIEW
This enduring activity has been designed for hematology-oncology teams, including hematologists, pathologists, nurses, and other multidisciplinary healthcare professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome. In particular, the education will help learners diagnose myelodysplastic syndrome earlier and accurately stratify risk; recognize potential resistance to initial therapy in patients with lower-risk myelodysplastic syndrome; and apply best evidence-based practices and clinical data for initial and second-line therapeutic decisions for lower-risk myelodysplastic syndrome.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary healthcare professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Interpret diagnostic criteria to enable early diagnosis of myelodysplastic syndrome with accurate risk stratification
- Evaluate the potential for resistance to initial therapy in patients with lower-risk myelodysplastic syndrome
- Use current evidence-based best practices and clinical data to inform choice of first- and second-line therapeutic options for patients with lower-risk myelodysplastic syndrome
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Faculty Member | Disclosures |
Maya Bloomberg, MSN | Discloses that she has received consulting fees from Bayer, Genentech, Sanofi, and Novo Nordisk. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 31, 2023
EXPIRATION DATE: October 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
FACULTY
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Harvard Medical School
Chief, Division of Leukemia
Dana-Farber Cancer Institute
Boston, MA
PROGRAM OVERVIEW
This enduring activity has been designed for hematology-oncology teams, including hematologists, pathologists, nurses, and other multidisciplinary healthcare professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome. In particular, the education will help learners diagnose myelodysplastic syndrome earlier and accurately stratify risk; recognize potential resistance to initial therapy in patients with lower-risk myelodysplastic syndrome; and apply best evidence-based practices and clinical data for initial and second-line therapeutic decisions for lower-risk myelodysplastic syndrome.
TARGET AUDIENCE
This program is designed to address the educational needs of the multidisciplinary hematology-oncology team, including hematologists, pathologists, nurses, and other multidisciplinary healthcare professionals working together to address the needs of patients with lower-risk myelodysplastic syndrome.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Interpret diagnostic criteria to enable early diagnosis of myelodysplastic syndrome with accurate risk stratification
- Evaluate the potential for resistance to initial therapy in patients with lower-risk myelodysplastic syndrome
- Use current evidence-based best practices and clinical data to inform choice of first- and second-line therapeutic options for patients with lower-risk myelodysplastic syndrome
ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
Faculty Member | Disclosures |
Daniel J. DeAngelo, MD | Discloses that he has consulting fees from Amgen, Autolus, Blueprint Medicines, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, and Takeda. He has also received grant/research funding from AbbVie, Novartis, Blueprint Medicines, and GlycoMimetics. |
All relevant financial relationships have been mitigated.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Chris Drury, MA, MS, MBA, Medical Director for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Marissa Mays-Verman, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Alexis Klinger, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: October 31, 2023
EXPIRATION DATE: October 31, 2024
Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.